Nanexa AB, listed on the Spotlight Stock Market, is a nanotechnology drug delivery company that focuses on the development of PharmaShell®, which is a new and groundbreaking drug delivery system. Nanexa develops its own projects and has cooperation agreements with several pharmaceutical companies.
Nanexa AB (publ) is now conducting a preferential rights issue of units. Upon full subscription, the company will add approximately MSEK 45.5 to the share portion before issue costs. In addition, in February 2021, the company may add up to an additional MSEK 45 via newly issued warrants.
Law firm Lindahl has assisted Nanexa in the transaction as a legal advisor. Lindahl’s team consisted of Gunnar Mattsson (responsible partner), Amanda Sjöberg, Olov Kling, Jonas Lenhammar and Therese Norenäs.
